B cell depletion and BAFF receptor blockade with ianalumab (VAY736) for the treatment of moderate-to-severe systemic lupus erythematosus: a phase 2 randomised, double-blind, placebo-controlled trial with subsequent open-label treatment

Agmon-Levin, NancyIgnatenko, StanislavGordienko, AlexanderCortés-Hernández, JosefinaNarongroeknawin, PongthornRomanowska-Próchnicka, KatarzynaShen, NanCiferská, HanaKodera, MasanariCheng-Chung, Wei J.Leszczyński, PiotrLan, Joung-LiangMysler, EduardoWojciechowski, RafalTarr, TündeVishneva, ElenaChen, Yi-HsingKaneko, YukoFinzel, StephanieHoi, AlbertaOkada, MasatoKoolvisoot, AjcharaLee, Shin-SeokLie, DaiKaneko, HiroshiRojkovich, BernadetteSun, LingyunZotkin, EugenyViallard, Jean-FrancoiseLópez, Berta Paula MagallaresGhanshani, Swati AashishLau, CarolAvrameas, AlexandreSips, CaroleOliver, Stephen John2026-03-092026-03-092026Annals Of The Rheumatic Diseases. -85 : 3 (2026), p. 476-488. -Ann. Rheum. Dis. - 0003-49670003-4967https://hdl.handle.net/2437/405415B cell depletion and BAFF receptor blockade with ianalumab (VAY736) for the treatment of moderate-to-severe systemic lupus erythematosus: a phase 2 randomised, double-blind, placebo-controlled trial with subsequent open-label treatmentfolyóiratcikkopen access articlehttps://ebib.lib.unideb.hu/ebib/CorvinaWeb?action=cclfind&resultview=long&ccltext=idno+BIBFORM136071OrvostudományokKlinikai orvostudományokhttps://linkinghub.elsevier.com/retrieve/pii/S0003496725045479szerzőhttp://dx.doi.org/10.1016/j.ard.2025.11.0152026-03-09001708224300001105025241510